S,S-dimethyl-N-(3-chloropyrazin-2-yl)sulfilimine | 86536-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: S,S-dimethyl-N-(3-chloropyrazin-2-yl)sulfilimine
• 英文别名: S,S-dimethyl-N-(2-chloro-pyrazinyl)sulfilimine；(3-chloropyrazin-2-yl)imino-dimethyl-λ4-sulfane
• CAS: 86536-74-5
• 化学式: C₆H₈ClN₃S
• 分子量: 189.669
• InChiKey: CGBOBINVUITMEU-UHFFFAOYSA-N

物化性质

• 熔点：
  106-108 °C
• 沸点：
  342.2±52.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  S,S-dimethyl-N-(3-chloropyrazin-2-yl)sulfilimine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.67h， 生成 2-氯-3-亚硝基吡嗪
  参考文献：
  名称：

  Synthesis and activity of novel nitropyrazines for use as hypoxic cell radiosensitizers

  摘要：

  A series of eight novel nitropyrazines has been prepared by oxidation of sulfoximine intermediates. The partition coefficient, one-electron reduction potential, sensitizer enhancement ratio, and chronic and acute aerobic cytotoxicity have been measured for each. Two representatives of this series were tested in the Ames test and were not found to be mutagenic.

  DOI：

  10.1021/jm00378a018
• 作为产物：
  描述：

  2-氯-3-氨基吡嗪 、 二甲基亚砜 在 trifluoromethanesulfonic acid anhydride 作用下， 生成 S,S-dimethyl-N-(3-chloropyrazin-2-yl)sulfilimine
  参考文献：
  名称：

  在硝基吡嗪和硝基喹喔啉中用3-氨基-1,2-丙二醇进行亲核取代

  摘要：

  用3-氨基-1，2-丙二醇处理2-氯-3-硝基吡嗪和2-氯-5-硝基吡嗪，得到的产物是氯化物的取代，而3-硝基吡嗪酸甲酯和2-氯-3-的类似反应硝基喹喔啉可提供干净的硝基取代基。6-氯-3-硝基吡嗪酸甲酯的类似反应提供了一种混合物，该混合物含有竞争性取代氯化物和亚硝酸盐的产物。

  DOI：

  10.1002/jhet.5570200419

文献信息

• [EN] BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES BICYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2013078254A1

  公开（公告）日：2013-05-30

  The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula 1: wherein Het, X, R1 and R2 are as defined herein.

  本发明提供了化合物，包括已分离的对映体、已分离的异构体、溶剂合物和其药学上可接受的盐，其化学式如下：其中Het、X、R1和R2的定义如本文所述。
• Lonidamine analogues and their use in male contraception and cancer treatment
  申请人：Georg I. Gunda

  公开号：US20060047126A1

  公开（公告）日：2006-03-02

  Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

  用于抑制精子生成和癌症治疗的新化合物，特别是作为热休克蛋白和/或延长因子1α的抑制剂。
• 2,6-disubstituted derivatives of 3-nitropyrazines useful as adjuncts to
  申请人：Merck & Co., Inc.

  公开号：US04609659A1

  公开（公告）日：1986-09-02

  2,6-Disubstituted derivatives of 3-nitropyrazine are disclosed to have activity in increasing the sensitivity of tumor cells to radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.

  本发明揭示了3-硝基吡嗪的2,6-二取代衍生物具有增加肿瘤细胞对辐射敏感性的活性。还揭示了制备这种化合物的方法和包括这种化合物的制药组合物。
• LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT
  申请人：Georg Ingrid Gunda

  公开号：US20110060003A1

  公开（公告）日：2011-03-10

  Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

  生育管理可以包括：根据公式I的一个或多个剂量给予受试者一种化合物，以降低受试者的生育能力。生育管理还可以包括给予化合物的有效量：破坏雄性受试者的精原细胞功能；抑制受试者的精子生成；减少受试者的睾丸重量；减少雌性受试者的卵巢重量；减少雌性受试者的血清孕酮；破坏雌性受试者的卵巢滤泡功能；导致受试者可逆的生育能力。为了恢复生育能力，该方法可以包括停止给予化合物以使受试者恢复生育能力。该化合物可以用于对受试者进行不可逆的绝育。
• LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
  申请人：Georg Ingrid Gunda

  公开号：US20090197911A1

  公开（公告）日：2009-08-06

  Lonidamine derivatives can be useful in methods of treating, inhibiting, and/or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and/or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives for inhibiting CFTR and/or Hsp90 or biological pathway thereof. Also, the method can include administering the lonidamine derivatives in a therapeutically effective amount for inhibiting ErbB2, Src, Raf-1, B-Raf, MEK, Cdk4, NKCC1, or combinations thereof. For example, the therapeutically effective amount of the lonidamine derivatives can be configured so as to provide a concentration in or adjacent to a kidney cell of about 0.25 uM or more or less.

  Lonidamine衍生物可用于治疗、抑制和/或预防多囊肾病（PKD）的方法中。因此，可以在治疗上有效的剂量下向受体内投入Lonidamine衍生物以抑制和/或预防多囊肾病（PKD）。这可以包括向受体注射治疗上有效的Lonidamine衍生物剂量以抑制CFTR和/或Hsp90或其生物途径。此外，该方法可以包括向受体注射治疗上有效的Lonidamine衍生物剂量以抑制ErbB2、Src、Raf-1、B-Raf、MEK、Cdk4、NKCC1或其组合。例如，Lonidamine衍生物的治疗上有效的剂量可以配置为在或邻近肾细胞中提供约0.25 uM或更高或更低的浓度。